Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Infection of B cells with Epstein-Barr virus (EBV) leads to proliferation and subsequent immortalization, resulting in establishment of lymphoblastoid cell lines (LCL) in vitro. Since LCL are latently infected with EBV, they provide a model system to investigate EBV latency and virus-driven B cell proliferation and tumorigenesis1. LCL have been used to present antigens in a variety of immunologic assays2, 3. In addition, LCL can be used to generate human monoclonal antibodies4, 5 and provide a potentially unlimited source when access to primary biologic materials is limited6, 7. A variety of methods have been described to generate LCL. Earlier methods have included the use of mitogens such as phytohemagglutinin, lipopolysaccharide8, and pokeweed mitogen9 to increase the efficiency of EBV-mediated immortalization. More recently, others have used immunosuppressive agents such as cyclosporin A to inhibit T cell-mediated killing of infected B cells7, 10-12. The considerable length of time from EBV infection to establishment of cell lines drives the requirement for quicker and more reliable methods for EBV-driven B cell growth transformation. Using a combination of high titer EBV and an immunosuppressive agent, we are able to consistently infect, transform, and generate LCL from B cells in peripheral blood. This method uses a small amount of peripheral blood mononuclear cells that are infected in vitroclusters of cells can be demonstrated. The presence of CD23 with EBV in the presence of FK506, a T cell immunosuppressant. Traditionally, outgrowth of proliferating B cells is monitored by visualization of microscopic clusters of cells about a week after infection with EBV. Clumps of LCL can be seen by the naked eye after several weeks. We describe an assay to determine early if EBV-mediated growth transformation is successful even before microscopic clusters of cells can be demonstrated. The presence of CD23hiCD58+ cells observed as early as three days post-infection indicates a successful outcome.

[1]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[2]  Sumita Bhaduri-McIntosh,et al.  Identification of a sub-population of B cells that proliferates after infection with epstein-barr virus , 2011, Virology Journal.

[3]  Heidemarie Neitzel,et al.  A routine method for the establishment of permanent growing lymphoblastoid cell lines , 1986, Human Genetics.

[4]  J. Rotter,et al.  Epstein-Barr virus transformation of cryopreserved lymphocytes: prolonged experience with technique. , 1991, American journal of human genetics.

[5]  A G Bird,et al.  Characteristics of Epstein-Barr virus activation of human B lymphocytes , 1981, The Journal of experimental medicine.

[6]  M. Ventura,et al.  Use of a simple method for the Epstein-Barr virus transformation of lymphocytes from members of large families of Réunion Island. , 1988, Human heredity.

[7]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[8]  J. Robinson,et al.  Efficiency of transformation of lymphocytes by Epstein-Barr virus. , 1977, Virology.

[9]  J. Cohen,et al.  Generation of Epstein‐Barr Virus (EBV)–Immortalized B Cell Lines , 1991, Current protocols in immunology.

[10]  C. Jun,et al.  An efficient method for the rapid establishment of Epstein‐Barr virus immortalization of human B lymphocytes , 2003, Cell proliferation.

[11]  Antonio Lanzavecchia,et al.  Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells , 2002, Science.

[12]  M. Pfreundschuh,et al.  Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. , 2002, Human gene therapy.

[13]  R. Küppers B cells under influence: transformation of B cells by Epstein–Barr virus , 2003, Nature Reviews Immunology.

[14]  G. Lenoir,et al.  Human blymphocytes immortalization by epstein-barr virus in the presence of cyclosporin a , 1986, In Vitro Cellular & Developmental Biology.

[15]  G. Miller,et al.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. , 1972, Proceedings of the National Academy of Sciences of the United States of America.